Hot off the Forge
-
The presentation features CEO Timothy J. Miller, Ph.D., Chief Medical Officer Maria Escolar, M.D., and Chief Technical Officer David Dismuke,…
-
“John is a seasoned biotech executive, bringing over 20 years of expertise and a proven track record in gene and…
-
Forge’s CEO will provide a company overview, detailing the company’s growth from its launch in July 2020 with $40 million…
-
Dr. David Dismuke, CTO will present, “Development of pEMBR™—An Improved Adenovirus Helper Plasmid for AAV Production.”
-
“We believe that focusing entirely on gene therapy will allow us to best serve our clients and patients by efficiently…
-
Forge Chief Executive Officer, President, CEO Timothy J. Miller, Ph.D., will be joined by David Dismuke, Ph.D., Chief Technical Officer, in…
-
“I’m honored to be presenting alongside a lineup of industry leaders and to share the groundbreaking progress that Forge Biologics…
-
Forge is now actively recruiting patients for enrollment in the RESKUE phase 1/2 clinical trial of FBX-101.
-
Forge to initiate a Phase 1/2 clinical trial evaluating its novel, first-in-human AAV gene therapy, FBX-101, for patients with Krabbe…
-
Expansion of the leadership team to strengthen expertise in AAV manufacturing, regulatory affairs, and financial operations.
-
Forge will use the proceeds to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021.